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Objectives: Molecular mechanisms linking autonomic dysfunction with poorer clinical 
outcomes in critical illness remain unclear. We hypothesized that baroreflex dysfunction 
alone is sufficient to cause cardiac impairment through neurohormonal activation of 
(NADPH oxidase-dependent) oxidative stress resulting in increased expression of G-protein 
coupled receptor kinase (GRK)-2, a key negative regulator of cardiac function. 
Design: Laboratory/clinical investigations. 
Setting:  University laboratory/medical centers.  
Subjects: Adult rats; wild-type/NAPDH oxidase subunit-2 (NOX-2) deficient mice; elective 
surgical patients. 
Interventions: Cardiac performance was assessed by transthoracic echocardiography 
following experimental baroreflex dysfunction (BD, sino-aortic denervation) in rats and 
mice. Immunoblots assessed GPCR recycling proteins expression in rodent cardiomyocytes 
and patient mononuclear leukocytes. In surgical patients, heart rate recovery after cardio-
pulmonary exercise testing, time/frequency measures of parasympathetic parameters were 
related to the presence/absence of BD (defined by spontaneous baroreflex sensitivity of 
<6ms.mmHg-1).  The associations of BD with intraoperative cardiac function and outcomes 
were assessed.  
Measurements and Main Results: Experimental BD in rats and mice resulted in impaired 
cardiac contractility and upregulation of GRK-2 expression. In mice, genetic deficiency of 
gp91 NADPH-oxidase (NOX-2) subunit prevented upregulation of GRK-2 expression in 
conditions of BD and preserved cardiac function. BD was present in 81/249 (32.5%) patients, 
and was characterized by lower parasympathetic tone and increased GRK-2 expression in 
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mononuclear leukocytes. BD in patients was also associated with impaired intraoperative 
cardiac contractility. Critical illness and mortality were more frequent in surgical patients 
with BD (relative risk: 1.66 [95%CI:1.16-2.39]; p=0.006). 
Conclusions: Reduced baroreflex sensitivity is associated with NOX-2 mediated upregulation 
of GRK-2 expression in cardiomyocytes and impaired cardiac contractility. Autonomic 





Maintenance of biologic variability is strongly associated with health and preservation of 
organ function. (1) Physiologic variability is modulated by the autonomic nervous system, 
perturbations of which occur at the onset of pathophysiologic insults resulting in critical 
illness regardless of etiology. Several features of established critical illness are compatible 
with a direct mechanistic role for autonomic dysfunction in causing multi-organ dysfunction, 
although patient data exploring this hypothesis remain limited. Prolonged bed rest (even in 
healthy volunteers) induces rapid detrimental changes in baroreflex autonomic control, (2) 
which is associated with excess morbidity and mortality during critical illness. (3) A key 
feature of experimental baroreflex dysfunction is reduced vagal activity, (4-6) which may 
also contribute to the phenotype of critically ill patients.(7) Concomitantly, impaired 
cardiometabolic responses to beta-adrenoceptor stimulation are robust negative prognostic 
biomarkers for survival in established critical illness. (8) However, unifying molecular 
mechanisms directly linking dysautonomia and cardiovascular dysfunction are lacking.  
Neurohormonal dysregulation in disease states where biological variability is altered results 
in alterations in G-protein coupled receptor signalling, which regulate G protein-coupled 
receptor (GPCR) trafficking through phosphorylation-dependent and independent 
mechanisms.(9) Impaired GPCR signaling and trafficking is responsible for the loss of 
inotropy observed in experimental models of cardiac failure. GPCR-kinase 2 (GRK2) 
expression increases when cardiomyocytes are subjected to oxidative stress.(10) 
Neurohormonal activation associated with the loss of biologic variability may contribute to 
cardiac oxidative stress, since elevated plasma angiotensin generates reactive oxygen 
species (ROS) via activation of NADPH-oxidase (NOX-2) in cardiovascular pathology. (11) 
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NOX-derived, ROS-induced ROS release may disrupt mitochondrial electron transport chain 
or alter mitochondrial ionic homeostasis. (12) 
 
In this study we tested the hypothesis that baroreflex dysfunction predisposes to the 
development of impaired cardiac contractility reported in established critical illness through 
altered expression of G-protein coupled receptor kinases and increased oxidative stress. To 
determine whether laboratory observations were clinically translational, we also identified 
impaired baroreflex sensitivity and associated parasympathetic dysfunction in patients 
undergoing major elective surgery to assess whether similar GPCR and autonomic 
dysfunction phenotypes were present in patients at risk of developing critical illness 








Detailed methods are described in the online supplement, including summaries 
demonstrating adherence to STROBE and ARRIVE guidelines. All research involving human 
participants was approved by Institutional Review Boards. Patients who underwent 
cardiopulmonary exercise testing as part of their enrollment in clinical trials at University 
College London Hospital (POM-O trial (13)) and Derriford Hospital, Plymouth (COMPETE-C 
trial (14); Supplementary Material) were assessed. 
 
Rodent Experiments 
All experiments were performed in accord with the UK Animals (Scientific Procedures) Act 
(1986) and ARRIVE guidelines (see Supplementary tables 2, 3 for summary of numbers and 
experiments). Male juvenile Sprague Dawley rats (Charles River, UK) and NOX-2 deficient 
and wild-type mice developed on a C57BL/6J background (King's College London British 
Heart Foundation Centre, London, United Kingdom) were used.  In a randomized manner, 
carotid sinus and aortic depressor nerves were sectioned bilaterally (sino-aortic 
denervation: SAD) in aseptic conditions under isoflurane anesthesia. (15) In sham-operated 
rats and mice, nerves were exposed and left intact. All experimental data were analyzed on 
an intention-to-treat basis, and thus all nerve ablations were considered as achieving SAD.  
Transthoracic echocardiography 
Transthoracic echocardiography (Vevo 770, Visualsonics, Canada-mice; Vivid 7; GE 
Healthcare, UK- rats) was performed under isoflurane anesthesia at 4-6 days and 3 weeks 
after SAD or sham surgery. Bolus doses of dobutamine were administered to assess cardiac 
contractility. All measurements were obtained by an investigator blinded to the identity of 
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the experimental groups.  
 
Blood pressure measurements 
Tail cuff blood pressure measurements were made non-invasively (CODA, Kent Scientific, 
Torrington, VT, USA) under 2% isoflurane anaesthesia.  All measurements were obtained by 
an investigator blinded to the identity of the experimental groups. 
 
Immunoblots 
Using antibodies against GRK2 (C-9) (Santa Cruz, sc-13143; (16)) GRK5 (C-20) (Santa Cruz, sc-
565; (17)), pan-arrestin (Abcam, ab2914; (18)), β-Arrestin 1 (D8O3J; Cell Signalling 
Technology, #12697), β-Arrestin 2 (C16D9; (Cell Signalling Technology,#3857) and phospho-
Troponin I (Cardiac) (Ser23/24) antibody (Cell Signalling Technology, #4004),  respective 
proteins were immunodetected from cell lysates prepared from cardiac ventricular tissue in 
rats and mice 2-3 weeks after the surgeries or mononuclear cells obtained from patients 
and prepared using Ficoll density gradient centrifugation. Proteins were resolved on SDS-
PAGE gels. Densitometry determinations were calculated as the ratio between the protein 
and α-tubulin or phosphofructokinase protein expression.  
 
Quantitative PCR 
RNA was extracted from rodent left ventricles using the RNeasy Maxi Kit (Qiagen, Crawley, 
UK). Total RNA (2 µg) was reverse-transcribed using a Taqman reverse transcriptase kit. 
cDNA (20 ng) was added to each well of a polymerase chain reaction array for quantitative 
polymerase chain reaction performed (Masterplex® realplexthermal cycler; Eppendorf, 
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Germany). The comparative Ct method (2-∆∆Ct) was used, with hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) or cyclophilin as the housekeeping gene. For samples 
obtained from sham-operated and SAD animals, evaluation of (2-∆∆Ct) was defined as the 
fold change in gene expression relative to the rat cerebral cortex. Primers are detailed in 
Supplementary Table 4. 
Patient studies 
Assessment of Baroreflex sensitivity 
Using a validated sequence method (one beat lag) technique (19), spontaneous baroreflex 
sensitivity was measured in surgical patients who had previously undergone 
cardiopulmonary exercise testing from optimally damped intra-arterial pressure recordings 
(Lidco Plus, London, UK) obtained immediately preoperatively. No minimum thresholds 
were used for changes in systolic blood pressure or pulse interval; events were accepted 
provided the correlation coefficient between systolic blood pressure and pulse interval 
exceeded 0.85. To avoid bias, all cardiopulmonary exercise and autonomic data analyses 
were undertaken by investigators blinded to clinical outcomes. Baroreflex values associated 
with increased mortality in multiple-organ dysfunction syndrome were stratified patients as 
having low/abnormal or normal BRS.(3)  
 
Assessment of parasympathetic vagal activity 
To determine parasympathetic (vagal) activity, two principle methods were employed. 
Firstly, heart rate recovery following exercise was measured as part of patients undergoing 
preoperative symptom-limited maximal cardiopulmonary exercise testing, with on-line 
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breath-by-breath gas analysis monitoring. The anerobic threshold (AT), measured as body 
mass-corrected oxygen consumption (ml.kg-1.min-1) was used as a marker of aerobic fitness 
(20). AT was determined by the modified V slope method and confirmed with the 
ventilatory equivalents method. Abnormal heart rate recovery following exercise was 
defined according to BRS values and related to previous studies that demonstrated the 
negative prognostic power of a heart rate reduction of ≤12 beats per minute from peak 
exercise to that measured one minute after cessation of exercise. (21) Secondly, Holter 
recordings were made preoperatively in a quiet environment using three-lead 
electrocardiographic recordings (Lifecard CF digital Holter monitors, Spacelabs Healthcare, 
Hertford, UK). Data cleaning and analysis was undertaken masked to cardiopulmonary 
exercise testingdata. Valid segments of recordings were identified from patients. Data 
quality criteria were in accordance with Task Force guidelines.(22) We assessed both time- 
and frequency domain measures from 5 min recordings in non-ventilated patients, although 
time-domain measures are preferable when only short-term recordings are possible since 
these are highly reproducible over time in a non-laboratory setting. (23)  Two time-domain 
measures of parasympathetic activity were assessed: the square root of the mean of the 
sum of the squares of the successive differences between adjacent beat-to-beat intervals 
(root mean square of the successive differences, RMSSD); and the proportion of number of 
pairs of successive beat-to beat intervals that differ by more than 50 ms, divided by total 
number of beat-to-beat intervals (pNN50). Spectral analysis of high frequency (HF) values, 
indicative of parasympathetic activity, was also performed (Spacelabs analysis software). To 
avoid bias, all autonomic data analyses were undertaken by investigators blinded to 
cardiopulmonary exercise test results and clinical outcomes. 
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Intraoperative cardiac performance 
To assess the impact of baroreflex dysfunction on cardiac performance, we re-examined 
hemodynamic data from the COMPETE-C trial. (14) Comparison of intraoperative 
hemodynamic changes between groups measured by esophageal Doppler flow (CardioQTM, 
Deltex Medical, Chichester, UK) was restricted to those patients who underwent open 
laparotomy at timepoints free of acute surgical or anesthetic interventions.  
 
Patient outcomes 
Severity of postoperative complications in the COMPETE-C trial were categorized by two 
independent analyzers, according to the Clavien-Dindo grade (Supplementary Table 6). 
Diagnostic criteria for sepsis, critical care utilization and time to discharge have previously 
been reported by the COMPETE-C investigators. 
 
Statistical methods 
The primary outcome in the patient study was length of hospital stay stratified according to 
the presence or absence of heart rate recovery as defined by low BRS. Pre-defined 
secondary outcome measures were severe (>grade 3 Clavien-Dindo) complications, 
postoperative sepsis and requirement at any point for admission to critical care. Power 
calculations for the clinical study design are provided in online supplement. Experimental 
rodent studies were designed in accordance with ARRIVE. For continuous data, normality of 
distribution was assessed and, where appropriate, analysed with ANOVA. Nonparametric 
data were analysed with the Mann–Whitney U-test. Length of hospital stay was estimated 
using the Kaplan-Meier method and analysed using the Cox proportional hazard model 
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(taking into account autonomic phenotype and randomization arm in the COMPETE-C trial). 
All reported p values are two-sided. Statistical analyses were performed using NCSS 8 
(Kaysville, UT). Median values (interquartile range) are presented, unless stated otherwise. 
Significance was accepted at p values ≤0.05. 
 
RESULTS 
Baroreflex dysfunction results in impaired cardiac contractility  
We first determined whether baroreflex dysfunction (3 weeks after SAD surgery) impairs 
cardiac function. We chose the 3 week timepoint to reflect the typical period over which 
chronic critical illness becomes established. Baroreflex dysfunction was induced by bilateral 
sectioning of aortic and carotid sinus nerves (hereafter, termed SAD: sino-aortic 
denervation).  Rats which underwent SAD surgery appeared clinically unwell as adjudged by 
their appearance (mild piloerection, hunched) in the first 3 days following nerve ablation. 
During the subsequent 3 weeks, SAD rats gained less weight (Figure 1A). Using a protocol 
(Figure 1B) similar to that used in humans (24), we found that established SAD assessed 3 
weeks after the surgery was associated with an impaired inotropic response (Figure 1C). The 
increase in cardiac output as a result of preserved contractile response to dobutamine was 
only observed in sham-operated rats.  Dobutamine elicited a relative tachycardia in SAD rats 
yet failed to elicit an inotropic response (Supplementary Figure 1).   
 
Enhanced cardiac GRK expression following baroreflex dysfunction. 
In view of the loss of the beta-1 adrenoceptor response to dobutamine in both human 
critical illness (8) and our baroreflex dysfunction model, we hypothesized that cardiac 
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impairment is due to impaired GPCR signaling similar to that observed in experimental 
models of cardiac failure. (25) Protein expression of both GRK-2 (Figure 2A) and β-arrestin-1 
(Figure 2B) was upregulated in SAD rat ventricular cardiomyocytes, whereas no change was 
seen in GRK-5 expression (Figure 2C, D). SAD is known to be associated with transient (but 
not chronic) - elevations in the level of circulating angiotensin. (26) We therefore 
hypothesised that angiotensin is likely to be responsible for producing cardiac dysfunction in 
SAD model through angiotensin-induced reactive oxygen species (ROS) generation, via 
activation of NOX-2.(11) We found that expression of angiotensin-II receptor 1a is 
upregulated in conditions of baroreflex dysfunction (Figure 2E). 
 
NOX2 activity triggers GRK2 expression in conditions of baroreflex dysfunction 
We next tested the hypothesis that SAD impairs cardiac function through angiotensin -
induced oxidative stress, via activation of NADPH-oxidase (NOX-2). Transthoracic 
echocardiography showed that NOX2 deficiency prevents cardiac impairment that 
developed in wild-type SAD mice (Figure 3A), where a significant 20% reduction in ejection 
fraction was observed (Figure 3B) despite similar blood pressures between genotypes 
(Figure 3C). In the failing heart, PKA activity is altered as a result of dysfunctional beta-
adrenoreceptor signalling.(9) This results in decreased troponin I phosphorylation 
(ser23/24), which was lower in wild-type mice following SAD (Figure 3D). Quantitative PCR 
of cardiomyocytes showed that both GRK-2 (Figure 3E) and GRK-5 (Figure 3F) mRNA was 
only upregulated in wild-type mice ten days after SAD, but not in NOX2-deficient murine 
cardiomyocytes. Protein expression of GRK-2, but not GRK-5, mirrored the transcriptomic 
changes observed in wild-type murine cardiomyocytes following SAD (Figure 3G). We also 
14 
 
observed differences in beta-arrestin 1 mRNA transcription in NOX2-deficient murine 
cardiomyocytes following SAD (Figure 3I-J) 
 
Baroreflex dysfunction is associated with impaired vagal activity in patients at risk of 
developing postoperative critical illness 
Impaired baroreflex sensitivity is associated with generalized autonomic dysfunction, 
including reduced parasympathetic (vagal) activity in both laboratory models (6) and 
patients.(7) We confirmed that baroreflex dysfunction is associated with impaired vagal 
activity in this patient population (Figure 4A-E) by assessing five measures of 
parasympathetic activity in patients with normal and low (≤6ms.mmHg-1) spontaneous 
baroreflex sensitivity values. First, we assessed exercise-induced heart rate recovery in a 
cohort of matched patients with similar aerobic exercise capacity (Table 1). Patients with 
low BRS had heart rate recovery values (Figure 5A) similar to those defined by epidemiologic 
(21) and physiologic (27) studies that have identified heart rate recovery ≤12bpm as a 
robust independent prognosticator for worse clinical outcomes.  No pre-defined medical 
(cardiovascular) co-morbidities were associated with heart rate recovery ≤12bpm, including 
diabetes mellitus (Table 1). Three different time-domain measures of parasympathetic 
activity obtained from Holter recordings made preoperatively were similarly consistent, with 
impaired BRS associated with lower values for RR-interval (Figure 4B), RMSSD (Figure 4C) 
and pNN50 (Figure 4D). Spectral analysis of the high frequency component of heart rate 
variability also showed lower values for patients with BRS≤6ms.mmHg-1 (Figure 4E). In a 
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second separate patient cohort (Plymouth), the thresholds defined by BRS from the 
derivation cohort gave similar HRR values (Figure 4F). Thus, every parasympathetic measure 
undertaken demonstrated that low vagal activity was strongly associated with impaired 
baroreflex sensitivity. 
 
Baroreflex dysfunction in patients is associated with elevated expression of GRK2 in 
circulating mononuclear leukocytes 
As baroreflex dysfunction recapitulates many features of cellular dysfunction synonymous 
with established critical illness, we next tested whether we could find evidence for this in 
circulating leukocytes which are exposed to a similar neurohormonal environment as 
cardiomyocytes- as has been shown in cardiac failure patients.(9) GRK2 expression in 
circulating mononuclear cells has been shown to parallel expression of this GPCR recycling 
protein in cardiac (left ventricular) tissue biopsies in patients with both heart failure (28) 
and systemic arterial hypertension.(29) We found that parasympathetic dysfunction was 
associated with increased GRK2 expression in circulating mononuclear cells (Figure 4G) 
obtained preoperatively from surgical patients (Figure 4H).   
 
Autonomic dysfunction is associated with failure to increase cardiac contractility 
intraoperatively. 
We next asked whether autonomic dysfunction may explain the failure to achieve optimal 
hemodynamic performance following major surgery, which is associated with increased 
morbidity and prolonged hospital stay.(8) The COMPETE-C trial (14) failed to find any benefit 
of stroke volume optimization intraoperatively, and we therefore considered whether a 
16 
 
failure to increase cardiac contractility in patients with autonomic dysfunction may account 
for this. We therefore evaluated the relationship between autonomic dysfunction and 
intraoperative hemodynamic function by re-analyzing data from the COMPETE-C trial, 
where intraoperative hemodynamic data was collected in patients who had undergone 
preoperative cardiopulmonary exercise testing. Using the same threshold values we 
obtained for heart rate recovery as a surrogate for baroreflex dysfunction (Figure 4F), low 
HRR (≤10bpm) was observed in 81/249 (32.5%) patients who underwent preoperative 
cardiopulmonary exercise testing as part of the screening process for the COMPETE-C trial. 
Having established the prevalence of autonomic dysfunction as defined by abnormal heart 
rate recovery in this cohort (blinded to perioperative details), we next assessed the 
intraoperative hemodynamic performance of those patients who subsequently completed 
the COMPETE-C randomized controlled trial protocol (Table 2; n=175). Despite similar 
perioperative heart rates (Figure 5A) and mean arterial pressure (Figure 5B), cardiac 
contractility, measured using the esophageal Doppler, did not alter in patients with 
autonomic dysfunction (Figure 5C). The failure of patients with parasympathetic autonomic 
dysfunction to achieve optimal hemodynamic performance was associated with an excess of 
serious (Clavien-Dindo grade ≥3) postoperative complications (relative risk: 2.60 
(95%CI:1.18-5.74); p=0.014), more frequent episodes of sepsis (relative risk:2.70 [1.49-4.93]; 
p=0.001), increased use of critical care resources (relative risk:2.22 [1.15-4.30]; p=0.016) and 
prolonged hospital stay (unadjusted relative risk:1.42 (95%CI: 1.05-1.92); p=0.02; Figure 5D). 
Cox regression analysis showed that the association between prolonged hospital stay and 
parasympathetic autonomic dysfunction remained when controlling for hemodynamic 
therapy (relative risk:1.59 (95%CI: 1.13-2.24); p=0.006). Parasympathetic autonomic 
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dysfunction was also associated with higher mortality, extending to 600 days 
postoperatively (hazard ratio: 1.16 [0.84-1.60]; p=0.007; Figure 5E). 
 
DISCUSSION 
Autonomic dysfunction is associated with every stage of critical illness although its role as a 
trigger of this maladaptive state, rather than merely being a marker, has remained largely 
unexplored. By taking an integrative experimental approach, we found that by solely 
disrupting afferent autonomic signalling results in profound clinically-relevant, cellular 
features synonymous with the cardiac phenotype of critical illness. Patients with pre-
existing autonomic dysfunction (as measured by assessment of baroreflex and 
parasympathetic activity) undergoing elective major surgery manifest a similar phenotype, 
characterized by molecular and physiologic signatures of impaired cardiac contractility.  This 
dysautonomic phenotype is linked to an excess of infectious complications. This autonomic 
re-interrogation of the COMPETE-C trial explains an apparent disconnect between limited 
intraoperative cardiac performance and postoperative outcome.  
 
Cardiac dysfunction is a key feature of critical illness that correlates with poor outcomes. 
(30) An inability to mount an appropriate cardio-metabolic response to beta-adrenoceptor 
stimulation (using a dobutamine challenge test) is associated with increased mortality in 
critical illness (8, 24). Interestingly, autonomic dysfunction recapitulates this maladaptive 
phenotype, both in surgical patients with established autonomic dysfunction 
intraoperatively and in animal model with experimentally-induced autonomic dysfunction. 
Established cardiac failure is characterized at the molecular level by significant up-regulation 
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of GRK2 (31), a member of the GRK family of serine/threonine protein kinases that 
phosphorylate and desensitize GPCRs, which mediate the effects of beta-adrenoceptor 
stimulation. (9) In contrast, acute (32) and chronic inflammation associated with rheumatoid 
arthritis (33) have been linked with downregulation of GRK2 levels in monocytes.  Following 
agonist activation, GRKs rapidly phosphorylate GPCRs; through binding of arrestins to the 
phosphorylated receptors, the receptor is uncoupled from the G protein. (34) Prolonged 
agonist stimulation leads to persistent homologous receptor desensitization and hence the 
loss of receptor responsiveness. GRK2 inhibits pro-contractile signalling pathways by 
phosphorylating the beta-adrenoceptors and promoting beta-arrestin binding. (9) Mice 
lacking β-arrestin lose cardioprotective mechanisms that counteract prolonged mechanical 
stretch (35). Thus, the impaired baseline function and inotropic responses to beta-
adrenoceptor stimulation in the rat SAD model of baroreflex dysfunction are consistent with 
increased expression of GRK2 in cardiomyocytes. The upregulation of β-arrestin expression 
most likely reflects compensatory cell survival signaling strategy in the rat SAD model, 
triggered through activation of common GPCR pathways as a result of baroreflex 
dysfunction -induced activation of the angiotensin system. Consistent with this hypothesis, 
we also found no compensatory increase in β-arrestin in the murine SAD model, where a 
lower ejection fraction was observed in the wild-type mice with cardiac contractility was 
found to be markedly worse than in the rat model. However, in the murine SAD model we 
also found a compensatory upregulation of GRK5(36) in wild-type mice; increased levels of 
GRK-5 correlate positively with lower morbidity/mortality in human heart failure.(37) 
Resting plasma levels of angiotensin and vasopressin in sino-aortic denervated rats were 
previously found to be similar to that of sham-operated animals; however, various stressors 
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elicit marked increases in the plasma levels of both hormones. (38) We found that 
transcription of  angiotensin-II receptor type 1 is upregulated in SAD rats, consistent with 
the observation that expression of this receptor is positively correlated with blood pressure 
throughout multiple neuroendocrine tissues  in the spontaneously hypertensive rat. (39) 
Angiotensin infused at levels that do not alter systemic arterial blood pressure induce 
NOX2–mediated cardiac hypertrophy within two weeks  (40) NOX-2 activation also 
contributes to myocardial hypertrophy induced by other humoral factors commonly 
upregulated in critical illness.(11) Impaired contractility via excessive activation of NOX2 
may be due to increased expression of L-type calcium channels (41) and/or pathological 
changes in mechanosensitive stretch-induced calcium release.(42) Pathologically excessive 
activation of NOX-2 by angiotensin actions in the sarcolemma and T-tubules impairs ROS-
induced sensitization of the ryanodine receptor which regulates release of calcium from the 
sarcoplasmic reticulum to enhance calcium-induced calcium release. (42) Thus, pathologic 
activation of NOX-2 may prevent optimal calcium release in response to stretch, a critical 
mechanism which controls cardiac function as described by the Frank–Starling law of the 
heart. In the context of critical illness, deficiency of gp91phox attenuates myocardial 
depression following endotoxemia, (43) which also triggers rapid and profound alterations 
in baroreflex control.(44) In this study we employed both rat and mouse SAD models.  Sino-
aortic denervation in mice increases blood pressure variability dramatically (45) although 
some studies have reported, in contrast to other species, an increase in resting arterial 
blood pressure early after SAD.(5) This may affect cardiac contractility independently of 
other direct (neurohormonal) alterations in cardiac physiology. Thus, timing appears to be 
an important factor in the expression of a variable cardiovascular phenotype reported 
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following SAD in mice, and we, therefore, chose the 2-3 week timepoint as this appears to 
be compatible with the development of established critical illness. Other protective 
mechanisms through which the autonomic nervous system provides the neural conduit to 
enable inter-organ crosstalk cannot be excluded, including the prevention of gut barrier 
failure (46). Nevertheless, both mouse and rat SAD models demonstrated similar pattern of 
myocardial GRK2 upregulation, suggesting that this cellular pathophysiological process 
occurs independently of blood pressure changes. Consistent with this assertion, our results 
demonstrate that patients with parasympathetic autonomic dysfunction also exhibited 
elevated GRK2 expression in circulating mononuclear cells, independent of blood pressure. 
This study has a number of clinical implications. The autonomic phenotype we describe 
provides a rapidly testable, integrative, patient-centered physiological paradigm to enhance 
the clinical stratification of risk, elucidate mechanisms of established therapeutics and 
devise novel interventional targets. The BRS values reported herein are remarkably similar 
to those previously found to predict increased risk of mortality following multiple-organ 
dysfunction syndrome.(3) We provide mechanistic translational data that provides a biologic 
rationale that helps explain why inferior cardiac performance during stressor situations may 
lead to further clinical complications. Interestingly, several pharmacologic agents have 
reversed/attenuated this pathological autonomic phenotype in other clinical areas, for 
example heart failure- another syndrome similarly characterized by persistent 
neurohormonal activation and a pro-inflammatory state.(47) Our data also provide 
mechanistic insights into the results of recent exploratory trials which demonstrated better 
outcomes in critical illness, even though underlying mechanisms remained poorly 
understood. For example, beta-1 adrenoceptor blockade (48) and alpha-2 agonism (49) 
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exert significant autonomic effects that, in part, can reverse/prevent several features of the 
cardiac phenotype that develops during critical illness. Avoiding pharmacological and/or 
therapeutic interventions that promote dysautonomia and consequently increase iatrogenic 
complications is likely to be beneficial, including the avoidance of prolonged bed rest by 
adopting early mobilization of critically ill patients (50).   
Laboratory and clinical epidemiologic data demonstrated that augmented vagal 
(parasympathetic) activity limits cardiovascular morbidity and mortality. (51) Importantly, 
the presence of parasympathetic autonomic dysfunction in the human surgical study cohort 
was not associated with pathologies traditionally linked to autonomic dysfunction such as 
diabetes mellitus. This is perhaps unsurprising given the link between autonomic 
parasympathetic dysfunction and all-cause mortality.  Epidemiologic data demonstrating an 
association between hypertension and hospitalization for sepsis (52) is also consistent with 
the autonomic phenotype described here. 
 
In summary, we suggest that baroreflex autonomic dysfunction mimics key cardiovascular 
aspects of critical illness. These findings offer the potential for novel therapeutic paradigms 
that could limit the excess morbidity and mortality associated with critical illness. Similarly, 
avoiding or reducing iatrogenic, off-target consequences of treatments that provoke or 





Figure 1.  Cardiac performance in experimental afferent autonomic dysfunction in rats.  
(A) Loss of weight following sino-aortic denervation (SAD). (B) Summary of dobutamine 
protocol to assess cardiac performance at three weeks following SAD. (C) Dobutamine-
induced increases in left ventricular ejection fraction are observed in sham operated rats 3 
weeks after nerve ablation surgery. Data are presented as mean ± SE (n=4-6 rats per group). 
Asterisk indicates p<0.05; n.s. – not significant. 
 
Figure 2. GPCR signalling protein expression in left ventricular tissue following 3 weeks of 
experimental afferent autonomic dysfunction. (A) Representative immunoblot for rat 
cardiomyocyte GRK-2 (B) cardiomyocyte β-arrestin-1. (C) cardiomyocyte GRK-5 protein 
expression. (D) Group densitometry data for GRK2, β-arrestin-1 and GRK5 in sham and SAD 
rat left ventricular tissue, referenced to α-tubulin (mean±SE).  (E) Quantitative PCR showing 
upregulation of ATII-1R mRNA expression in SAD rat ventricular cardiomyocytes (referenced 
to LN229 neuronal cell line expression). *Significant difference (P<0.05); n=4-6/group. 
 
Figure 3. Afferent autonomic dysfunction promotes GRK2 over-expression via activation of 
NOX-2. (A) Representative M-mode echocardiography image showing impaired baseline 
contractility 26 days after sino-aortic denervated in a wild-type mouse, but preserved 
cardiac contractility 26 days after sino-aortic denervation in a representative NOX2 mutant 
mouse. (B) Population data for ejection fraction in wild-type or NOX-2-/- mouse following 
either sham or sino-aortic denervation procedure. 3-5/experimental group; mean±SE. 
*Significant difference (P<0.05). (C) Similar mean arterial pressure (measured by tail-cuff 
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occlusion) in anesthetized wild-type or NOX-2-/- mice. (D) Immunoblot showing reduction in 
phospho-troponin (Ser23/24) in wild-type cardiomyocytes 10 days after bilateral sino-aortic 
denervation. (E)  Quantitative PCR demonstrating upregulation of GRK2 mRNA expression in 
SAD wild-type cardiomyocytes (referenced to expression in mouse brain cortex samples). 
*Significant difference (P<0.01); n=4/group. (F)  Quantitative PCR demonstrating 
upregulation of GRK5 mRNA expression in SAD wild-type cardiomyocytes, same samples as 
shown in panel E (referenced to expression in mouse brain cortex samples). *Significant 
difference (P<0.01); n=4/group. (G) Representative immunoblot for GRK2 in murine wild-
type or NOX-2-/- ventricular cardiomyocytes, ten days after sham surgery or sino-aortic 
denervation (SAD).  Population data show change in GRK2 protein levels for SAD wild-type 
or NOX-2-/- ventricular cardiomyocytes, as relative change over mean sham protein levels (* 
P=0.07, unpaired t-test, n=4-6/group). (H) Representative immunoblot for GRK5 in murine 
wild-type or NOX-2-/- ventricular cardiomyocytes, ten days after sham surgery or sino-aortic 
denervation (SAD). (I) Quantitative PCR for β-arrestin 1 mRNA expression in SAD wild-type 
cardiomyocytes (referenced to expression in mouse brain cortex samples). *Significant 
difference (P<0.05); n=4/group. (J) Quantitative PCR for β-arrestin 2 mRNA expression in 
SAD wild-type cardiomyocytes (referenced to expression in mouse brain cortex samples). No 
significant differences were found between groups. 
 
Figure 4. Cardiopulmonary exercise performance to detect established preoperative 
baroreflex dysfunction.  
(A) Analysis of heart rate changes to determine heart rate recovery (HRR) as measure of 
parasympathetic cardiac activity in surgical patients undergoing preoperative 
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cardiopulmonary exercise testing. (B) Heart rate recovery in surgical patients undergoing 
preoperative cardiopulmonary exercise testing, stratified by normal or low spontaneous 
baroreflex sensitivity. (C) RR-(pulse) interval in surgical patients, stratified by normal or low 
spontaneous baroreflex sensitivity. (D) Root mean square of the successive differences 
(RMSSD) in surgical patients, stratified by normal or low spontanenous baroreflex 
sensitivity. (E) pNN50 in surgical patients, stratified by normal or low spontanenous 
baroreflex sensitivity. Asterisk denotes p≤0.01. (F) High frequency spectral analysis 
component of heart rate in surgical patients, stratified by normal or low spontanenous 
baroreflex sensitivity. (G) Heart rate recovery profiles in surgical patients enrolled into 
COMPETE-C hemodynamic trial, obtained following preoperative cardiopulmonary exercise 
testing (stratified by normal or low spontaneous baroreflex sensitivity). (H) Immunoblot for 
GRK2 protein expression in isolated mononuclear cells obtained from 3 consecutively 
recruited surgical patients undergoing preoperative cardiopulmonary exercise testing. (I) 
Group data for patient immunoblots performed in 10 separate subjects demonstrating each 
heart rate recovery phenotype (5/group). Median (25-75th centile) heart rate recovery 
values shown below the bars for patients with HRR threshold values stratified by original 
BRS data.*Significant difference (P<0.05). 
 
Figure 5.  Perioperative cardiovascular performance in patients with autonomic dysfunction.  
(A) Heart rate during perioperative period; blue-normal HRR, red- HRR<10bpm as defined in 
Figure 4A. (B) Mean arterial pressure during perioperative period. (C) Cardiac contractility 
(peak velocity) is impaired intraoperatively in patients with parasympathetic autonomic 
dysfunction defined by low HRR. (D) Prolonged hospital stay is observed in patients with 
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preoperative parasympathetic autonomic dysfunction, regardless of intraoperative 
hemodynamic management (relative risk: 1.59 (95%CI: 1.13-2.24); p=0.006).  GDT- patients 
randomized in COMPETE-C trial to goal directed therapy; AD: preoperative parasympathetic 
autonomic dysfunction. Values expressed as mean (SD). (E) Postoperative mortality is higher 
in patients detected to have parasympathetic autonomic dysfunction preoperatively after 
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